Many metabolic disturbances, such as protein-energy wasting, inulin resistance, and
dyslipidemia are common features of chronic kidney disease (CKD). However, to date, the
underlying mechanisms of these disturbances remain elusive. Many in vitro studies have
demonstrated that white adipose cells exhibit dysfunctions in conditions that mimics uremic
environment. In good agreement, several animal experiments have reported that chronic kidney
disease was associated with lipoatrophy, adipose tissue dysfunction and ectopic lipid
redistribution. The goal of this protocol is to collect and study structural and metabolic
properties of white adipose tissue in CKD stage V patients to evidence adipose tissue
dysfunction associated with CKD. The primary outcome measure will be the cellularity of the
adipose tissue (i.e. size of the adipose cells) and the secondary measure to study the gene
expression profile using microarray and metabolic properties of adipose tissue (i.e.
lipogenesis). To this end, 15 male adult volunteers and 15 non-diabetic and non-dialyzed CKD
stage V patients, matched for age, gender and body mass index (BMI) will be recruited at the
Departments of Nephrology or Urology of Lyon University Hospital (Lyon, France). The biopsies
of abdominal subcutaneous white adipose tissue (2-3 g) will be performed during elective
urologic surgery (i.e. peritoneal dialysis catheter for CKD patients and radical
prostatectomy for non CKD patients).
Other: Biopsy of abdominal subcutaneous white adipose tissue (2-3 g)
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT02902705
Ages eligible for Study
18 Years and older
Genders eligible for Study
Accepts Healthy Volunteers
CKD (Chronic Kidney Disease) and non-CKD patients:
At least 18 years of age
Able and willing to provide informed consent
Normal fasting glucose (less than 6 mmol/l )
No evidence of significant concurrent illness
BMI <30 kg/m2
Non acidotic (bicarbonate >20 mmol/L)
Normal coagulation profile CKD patients:
• eGFR (estimated Glomerular Filtration Rate)< 25 mL/min/m2 before the beginning of renal suppletion therapy Non-CKD patients:
• eGFR >50 mL/min/m2
A known diagnosis of diabetes mellitus
enrolled in a other study that may confound results of this study.
Have been treated with: corticosteroids or insulin or oral diabetic medications within 8 days prior to study entry
Unwilling and/or not able to give written consent
Patient with active systemic bacterial, viral or fungal infections
All locations for NCT02902705
Service de Néphrologie, dialyse, hypertension artérielle - Pavillon P - Hôpital Edouard Herriot -
Lyon, France, 69003
View full eligibility
Tris trial is registered with FDA with number: NCT02902705. The sponsor of the trial is Hospices Civils de Lyon and it is looking for 23 volunteers for the current phase.
Official trial title: Morphological and Functional Changes in White Adipose Tissue in Nondiabetic Chronic Kidney Disease Patients
1What's a trial
4Get in touch
What's a trial
Not sure you're well informed about clinical trials? Learn more about their benefits, risks and other important details.
Enter your details like condition, age, gender and other preferences and we will show you a list of all relevant clinical trials.
Review the summary of the selected clinical trial and all the locations near you in order to see if it's of interest to you.
Get in touch
You've found an interesting trial? We'll need a bit more information about you so we can connect you to the doctor in charge.
Some people want to consult their doctor before considering participation in a clinical trial. This is absolutely normal as your doctor should know your medical history and should be able to advise you. If you want you can easily share the information for this trial with your doctor by clicking on the button below.